Hormone Receptor-positive Breast Cancer
📧 Sign up to get email alerts when something new happens for Hormone Receptor-positive Breast Cancer.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2026-04-24Clinical Trial Update: Elacestrant With/Without Triptorelin in Premenopausal Women With Luminal Breast Cancer [Phase 2]
A Phase 2 clinical trial update evaluating elacestrant with or without triptorelin in premenopausal women with luminal, hormone receptor-pos…
-
CLINICAL_TRIALS research · 2026-04-23Clinical Trial Update: Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer [Phase 3]
This is a Phase 3 trial assessing the addition of durvalumab to standard chemotherapy for stage II-III breast cancer; the study is currently…
-
CLINICAL_TRIALS trial_result · 2026-04-21Clinical Trial Update: Phase III Study to Assess AZD9833+ CDK4/6 Inhibitor in HR+/HER2-MBC With Detectable ESR1m Before Progression (SERENA-6) [Phase 3]
A Phase 3 study (SERENA-6) is evaluating AZD9833 plus a CDK4/6 inhibitor in HR+/HER2-negative breast cancer with ESR1 mutation; the trial is…
-
CLINICAL_TRIALS research · 2026-04-21Clinical Trial Update: A Study of [225Ac]Ac-AKY-1189 in Patients With Solid Tumors [Phase 1]
Phase 1 trial evaluating [225Ac]Ac-AKY-1189 for solid tumors is currently recruiting, including urothelial carcinoma of the bladder and trip…
-
CLINICAL_TRIALS research · 2026-04-21Clinical Trial Update: A Study of the TheraBionic P1 Device in Breast Cancer [NA]
Clinical trial update indicates recruiting for a study of the TheraBionic P1 Device in breast cancer, including hormone receptor-positive an…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2026-04-20Clinical Trial Update: Zunsemetinib in Combination With Capecitabine in Patients With Hormone Receptor-Positive and HER2-Negative Metastatic Breast Cancer With Bone Metastasis [Phase 1, Phase 2]
A Phase 1/2 trial evaluating Zunsemetinib in combination with capecitabine for hormone receptor-positive, HER2-negative metastatic breast ca…
-
CLINICAL_TRIALS research · 2026-04-17Clinical Trial Update: A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced, Recurrent, or Metastatic HR+HER2- Breast Cancer(PANKU-Breast01) [Phase 3]
Phase 3 study comparing BL-B01D1 to chemotherapy of physician's choice in unresectable locally advanced, recurrent, or metastatic HR-positiv…
-
CLINICAL_TRIALS research · 2026-04-17Clinical Trial Update: A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032) [Phase 3]
A Phase 3 study of sacituzumab govitecan (Sac-TMT, MK-2870) for breast cancer is currently recruiting. The trial includes patients with trip…
-
CLINICAL_TRIALS research · 2026-04-17Clinical Trial Update: Ribociclib in Hormone Receptor-positive, HER2-negative Early Breast Cancer With Residual Disease After Neoadjuvant Chemotherapy [Phase 3]
Phase 3 trial evaluating ribociclib as adjuvant therapy in hormone receptor-positive, HER2-negative early breast cancer with residual diseas…
-
CLINICAL_TRIALS trial_result · 2026-04-17Clinical Trial Update: A Feasibility Trial of a Web Based App Intervention in Hormone Positive Breast Cancer Patients to Improve Adherence to Endocrine Therapy [NA]
This document notes the termination of a feasibility trial evaluating a web-based app to improve adherence to endocrine therapy in hormone r…
-
CLINICAL_TRIALS research · 2026-04-16Clinical Trial Update: Functional Imaging in Prediction of Response to Abemaciclib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer [Phase 2]
A Phase 2 trial evaluating whether functional imaging can predict response to abemaciclib in advanced hormone receptor-positive, HER2-negati…
-
CLINICAL_TRIALS research · 2026-04-15Clinical Trial Update: BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors [Phase 1]
This is a Phase 1 trial evaluating BGB-43395 alone or in combination for advanced breast cancer and other solid tumors. Recruitment is ongoi…
-
CLINICAL_TRIALS trial_result · 2026-04-13Clinical Trial Update: A Study on the Use of Fluzoparib Combined With Chemotherapy for Neoadjuvant Treatment of HRD-positive, HR+/HER2- Breast Cancer [Phase 2]
Phase 2 trial evaluating Fluzoparib plus chemotherapy as neoadjuvant therapy for HRD-positive, hormone receptor-positive/HER2-negative breas…
-
CLINICAL_TRIALS research · 2026-04-08Clinical Trial Update: Ribociclib And Endocrine Treatment of Physician's Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast Cancer [Phase 2]
Phase 2 clinical trial evaluating ribociclib in combination with endocrine therapy of physician's choice for locoregional recurrent, hormone…
-
CLINICAL_TRIALS trial_result · 2026-04-06Clinical Trial Update: Capecitabine In Combination With Cemiplimab In Patient With Metastatic Breast Cancer [Phase 1]
A completed Phase 1 trial evaluated the combination of capecitabine and cemiplimab in patients with metastatic breast cancer, including horm…
-
CLINICAL_TRIALS research · 2026-04-06Clinical Trial Update: A Vaccine (STEMVAC) With Standard Endocrine-Based Therapy or Chemotherapy for the Treatment of Metastatic Hormone Receptor Positive, HER2 Negative Breast Cancer [Phase 2]
Phase 2 trial evaluating STEMVAC in combination with standard endocrine therapy or chemotherapy for metastatic hormone receptor-positive, HE…
-
CLINICAL_TRIALS research · 2026-04-03Clinical Trial Update: Mobile Health for Adherence in Breast Cancer Patients [NA]
Clinical trial evaluating a mobile health tool to support adherence in breast cancer patients is currently recruiting, including HER2-negati…
-
CLINICAL_TRIALS research · 2026-04-03Clinical Trial Update: A Study to Assess CLBR001+ABBV-461 in Subjects With Locally Advanced or Metastatic Breast Cancer [Phase 1]
This clinical trial update describes a Phase 1 study evaluating the combination CLBR001 and ABBV-461 for locally advanced or metastatic brea…
-
CLINICAL_TRIALS research · 2026-04-02Clinical Trial Update: Safety and Efficacy of T-DXd vs. CDK4/6i-based ET as First-line Therapy of HR-positive and HER2-low/Ultralow Advanced Breast Cancer Patients Classified as Non-luminal Subtype [Phase 2]
A Phase 2 trial comparing trastuzumab deruxtecan versus CDK4/6 inhibitor–based endocrine therapy as first-line treatment for HR-positive, HE…
-
CLINICAL_TRIALS other · 2026-04-02Clinical Trial Update: A Single Arm Phase II Study of ADjuvant Endocrine Therapy, Pertuzumab, and Trastuzumab for Patients With Anatomic Stage I Hormone Receptor-positive, HER2-positive Breast Cancer [Phase 2]
A single-arm Phase II trial evaluating adjuvant endocrine therapy combined with pertuzumab and trastuzumab in patients with anatomic stage I…
-
CLINICAL_TRIALS research · 2026-04-01Clinical Trial Update: Pharmacokinetic Model of Abemaciclib: Correlation With Severe Diarrhea as the Primary Toxicity Endpoint in Patients With Localized Hormone Receptor-positive Breast Cancer [Phase 4]
This Phase 4 study assesses the pharmacokinetic model of abemaciclib and its correlation with severe diarrhea as the primary toxicity endpoi…
-
CLINICAL_TRIALS research · 2026-04-01Clinical Trial Update: Epidemiology and Treatment of HR+/HER2- Breast Cancer in England
A completed clinical trial update examining epidemiology and treatment patterns for HR+/HER2- breast cancer in England.
-
CLINICAL_TRIALS research · 2026-03-27Clinical Trial Update: A Study of Mutant Selective-Inhibitor (CGT6297), in Patients With Advanced Solid Tumors [Phase 1]
This is a Phase 1 study evaluating CGT6297, a mutant-selective inhibitor, in adults with advanced solid tumors, including PIK3CA-mutant endo…
-
CLINICAL_TRIALS research · 2026-03-25Clinical Trial Update: BGB-43395 Plus Letrozole Versus CDK4/6i Plus Letrozole for Patients With Advanced or Metastatic HR+/HER2- Breast Cancer Who Have Not Received Prior Treatment for Advanced or Metastatic Disease [Phase 3]
Phase 3 trial comparing BGB-43395 plus letrozole to a CDK4/6 inhibitor plus letrozole in first-line, advanced or metastatic HR+/HER2- breast…
-
CLINICAL_TRIALS research · 2026-03-23Clinical Trial Update: Using FDG-PET/CT to Assess Response of Bone-Dominant Metastatic Breast Cancer, FEATURE Study [Phase 2]
A Phase 2 clinical trial update describing the use of FDG-PET/CT to assess response in bone-dominant metastatic breast cancer (FEATURE study…